SPM
CRSP icon

Symmetry Peak Management’s CRISPR Therapeutics CRSP Stock Holding History

Symmetry Peak Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-25,300
Closed -$1.54M – 36
2019
Q4 		$1.54M Buy
+25,300
New +$1.38M 0.34% 48

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Symmetry Peak Management's CRSP Position: Q3 2020 in Review

Symmetry Peak Management sold out of CRISPR Therapeutics (CRSP) in Q3 2020, closing a stake of 3,500 shares — an estimated $257K sold.

Symmetry Peak Management first reported a position in CRSP in Q2 2020 and held it in 1 quarter. The position peaked at $257K in Q2 2020. 310 funds tracked by Wall St. Rank hold CRSP as of Q3 2020.

  • Symmetry Peak Management reported no remaining CRISPR Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Symmetry Peak Management sold 3,500 CRISPR Therapeutics shares in Q3 2020, an estimated $257K.
  • Symmetry Peak Management first reported a position in CRISPR Therapeutics in Q2 2020 and held it in 1 quarter.
  • Symmetry Peak Management's CRISPR Therapeutics position peaked at $257K in Q2 2020.
  • 310 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2020.

Based on Symmetry Peak Management's 13F filing for Q3 2020, filed 16 Nov 2020.